Pricing Debate
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
AstraZeneca Joins The $35 Club With Cap On Inhaler Copays
The British drug maker’s move follows that of Boehringer Ingelheim earlier this month, which itself followed increasing political scrutiny on out-of-pocket costs.
Stock Watch: Advanced Therapies Deliver Fourth-Quarter Flop
As drug pricing continues its ascent among hot button issues, the multi-million-dollar price tags for one-and-done advanced therapies, their justification and reimbursement all remain unaligned.
BIO Chair Ted Love On Drug Pricing And Political Pressure
Biopharma veteran Ted Love assured industry that the sector remains fundamentally strong during remarks at the BIO CEO & Investor Conference.
Sanofi Chief Issues Warning To Innovation-Unfriendly EU
Paul Hudson told Scrip that while the EU's prioritization on matters such as boosting hydrogen use and electric car batteries was laudable, delivery of healthcare and the innovation associated with it should be "a strategic imperative."
ICER Suggests Big Price Cut For Novartis’s New PNH Drug
The pricing watchdog said 94% of Fabhalta’s price comes from offsetting the cost of AstraZeneca’s Ultomiris, while Novartis said ICER’s analysis has “substantial challenges.”
Paying For Obesity Drugs: The Looming Affordability Crisis
As use of new obesity medicines become more widespread, experts at the J.P. Morgan Healthcare conference predicted that paying for them will stress state governments and employers.
What’s Next For ICER: An Interview With New President Sarah Emond
The Institute for Clinical and Economic Review’s new president talked to Scrip in an interview about cell and gene therapy, obesity drugs and the new Medicare drug price negotiation program.
The ‘Haves And Have-Nots’ Are Becoming Clearer In Cell And Gene Therapy
2023 saw a number of gene therapy companies go to the wall, but those that can combine clinical significance and commercial success can build sustainable businesses.
J.P. Morgan 2024: Optimism With An Undercurrent Of Tension
An uptick in deals and an improving macro-economic outlook laid the groundwork for a rosier sentiment across much of the industry at the annual health care conference.
Costs From ICER’s Unsupported Price Increase List Tick Back Up
Humira topped ICER’s list of drugs with unsupported price increases that added the most cost to the US health care system during 2022, its last year before biosimilars hit the US market.
Biden's Latest Rx Pricing Moves Are At Once Bold And Incremental
As the president’s reelection campaign themes take shape, the administration is preparing to leverage NIH patents in ways it had previously eschewed. As with the merger oversight effort, though, the germs of the plans began earlier in Biden’s tenure.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Bayer’s Phase III failure; US group seeks Japan changes; AstraZeneca winning AKT race for now; NASH developments at AASLD; and the Q3 impact of China’s corruption campaign.
PhRMA's Narasimhan Asks Japan To Reform Pricing Policies
Pointing to what it says is decreased R&D in Japan in contrast to the global market, PhRMA has again urged the country to revise its drug pricing policies and support innovation, while cautiously welcoming new moves to waive a requirement for Phase I trials in the country.
AstraZeneca CEO Soriot On Obesity, Gene Therapy And More
CEO Pascal Soriot fielded questions on a wide range of topics – from China to US Medicare drug price negotiations – at a media briefing in New York City.
Health Plan Transparency Still At Issue, ICER Finds
In its third annual report on fair access to prescription drugs, the US pricing watchdog found high concordance with some of its recommended policies, but thinks greater transparency is needed for a thorough assessment.
A Gloomy Outlook On Macro Trends From Industry CEOs
Pfizer CEO Albert Bourla, Eli Lilly CEO David Ricks and Seagen CEO David Epstein discussed pressing issues facing the pharmaceutical industry at the recent Galien Forum.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.